Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
Evaluate the safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with percutaneous hepatic perfusion in patients with liver metastases (but not restricted to) of malignant melanoma
Uveal Melanoma|Metastatic Cutaneous Melanoma
DRUG: Autologous Tumor Infiltrating Lymphocytes|DRUG: Melphalan|DRUG: Interleukin-2
Incidence and severity of adverse events, Graded according to Common Terminology Criteria for Adverse Events version 5.0, 5 years
Objective response rate, Defined as the proportion of patients with a best overall response of partial response or better defined by RECIST 1.1, 5 years|Progression-free survival, Defined as the time from inclusion to objective tumor progression (determined by RECIST 1.1), or death due to any cause, whichever occurred first., 5 years|hepatic Progression-free survival, Defined as the time from inclusion to objective tumor progression in the liver (determined by RECIST 1.1), or death due to any cause, whichever occurred first., 5 years|Duration of response, Defined as the time from the first documented response and the date of the first documented tumor progression, death, or the last tumor assessment that occurred before subsequent therapy., 5 years|Overall survival, Defined as the time from inclusion to the date of death due to any cause, 5 years|Evaluation of Tolerability, Defined as the proportion of patients included that receive PHP and TIL, 5 years
Evaluate the safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with percutaneous hepatic perfusion in patients with liver metastases (but not restricted to) of malignant melanoma